PBH
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E 14.54, PEG 1.82, Graham Number $57.42
- P/E is low
- Price is near Graham Number
- PEG ratio of 1.82 suggests overvaluation relative to growth
- Intrinsic value is far below market price
Ref Revenue Growth -2.40%, Earnings Growth -20.50%
- Forward P/E is lower than trailing P/E
- Negative YoY Revenue and Earnings growth
- Negative Q/Q growth trends
Ref 0/4 recent earnings beats
- Long history of earnings beats prior to 2024
- Recent shift to consistent earnings misses
- Poor 1-year price performance (-33%)
Ref Piotroski F-Score 4/9, Current Ratio 3.11
- Excellent Current Ratio (3.11)
- Low Debt/Equity (0.59)
- Piotroski F-Score is only 4/9 (Stable/Weak)
Ref Dividend Yield N/A
- No dividend payments
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PBH and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare Inc.
Primary
|
+24.3% | -10.8% | -33.0% | -9.1% | -4.5% | -6.5% |
|
LMAT
LeMaitre Vascular, Inc.
Peer
|
+140.7% | +121.7% | +42.2% | +33.8% | +6.0% | +5.7% |
|
HCM
HUTCHMED (China) Limited
Peer
|
-48.0% | -1.7% | +21.6% | +1.1% | +4.6% | -1.2% |
|
TARS
Tarsus Pharmaceuticals, Inc.
Peer
|
+97.5% | +298.6% | +19.2% | -10.2% | -9.3% | -4.4% |
|
NHC
National HealthCare Corporation
Peer
|
+173.9% | +222.3% | +87.0% | +43.5% | +8.5% | +1.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare Inc.
|
BEARISH | $2.61B | 14.54 | 10.3% | 16.9% | $55.09 | |
|
LMAT
LeMaitre Vascular, Inc.
|
NEUTRAL | $2.61B | 45.48 | 15.8% | 23.1% | $114.62 | Compare |
|
HCM
HUTCHMED (China) Limited
|
NEUTRAL | $2.62B | 5.75 | 45.2% | 83.3% | $15.24 | Compare |
|
TARS
Tarsus Pharmaceuticals, Inc.
|
NEUTRAL | $2.58B | - | -23.4% | -14.7% | $60.67 | Compare |
|
NHC
National HealthCare Corporation
|
NEUTRAL | $2.7B | 22.59 | 11.9% | 7.9% | $173.29 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-11 | ZERILLO JEFFREY | Officer | Sale | 1,000 | $65,930 |
| 2026-01-06 | ROSADO JOSE LUIS | Officer | Stock Award | 3,426 | - |
| 2025-12-01 | ZERILLO JEFFREY | Officer | Sale | 1,000 | $60,000 |
| 2025-11-25 | BYOM JOHN E | Director | Sale | 3,000 | $178,050 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning PBH from our newsroom.